Lifetime Sciences

Lifetime Sciences is a biotechnology and life sciences company founded in 2015 and headquartered in the United States. The company, formerly known as MyGenetx, is a CAP-accredited and CLIA-certified laboratory that specializes in molecular and advanced diagnostic testing, positioning itself as the primary resource for transitioning and implementing precision-guided medicine. The company's medical team comprises experts in research and clinical product development for genetics, emphasizing their commitment to innovation and cutting-edge technology. One of their notable offerings is MyPGt™, a pharmacogenetic panel designed to determine an individual's medication metabolism. This addresses the limitations of traditional "one size fits all" dosing strategies, which can result in adverse drug reactions or drug inefficacy. Additionally, MyHap2™ is a proprietary genetic test developed by Lifetime Sciences to assess the risk of heart attacks in patients with diabetes. As of now, there is no information available regarding the last investment or the investors involved. Nevertheless, Lifetime Sciences presents a compelling proposition in the field of advanced diagnostic testing, and its specialized focus on precision guided medicine positions it as a promising player in the biotechnology and life sciences industry. The company's dedication to molecular testing and personalized medicine aligns with the growing demand for innovative healthcare solutions, making it an intriguing prospect for potential investors within the life sciences sector.